ADDRESSING BARRIERS IN

Advancing Equitable Biomarker Testing in Community Oncology

Wednesday, October 16, 2024

Doors open: **11:30 AM PT**

Presentation: **12:00–1:30 PM PT**

MGM Grand Hotel and Convention Center

Room: Terrace 151

CME OUTFITTERS

ADDRESSING BARRIERS IN

Advancing Equitable Biomarker Testing in Community Oncology

Activity Description

Biomarker and molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and in underserved communities. At present, patients with cancer in racially or ethnically underserved communities are not receiving biomarker testing at the same rate as White patients in communities with greater access to care. Barriers to testing include insurance restrictions, conflicting guidelines, and the reliance of community oncologists on single-gene testing instead of the multi-gene panels that are used more often by academic oncologists. In the multidisciplinary setting of community oncology, healthcare professionals (HCPs) would benefit from education on best practice models that provide cost-effective molecular testing services for the undertested underserved population, especially given that more recently U.S. Food and Drug Administration (FDA)-approved treatments require biomarker testing.

In this CME Outfitters live symposium, expert faculty will evaluate the latest biomarker testing strategies in prostrate, bladder, and lung cancer; discuss how to integrate all members of the interdisciplinary care team in community oncology settings; identify root causes of health inequity in cancer care; and review strategies to address barriers that prevent the uptake of biomarker testing services in cancer care management.

Target Audience

Managed care professionals including physician medical directors and pharmacists

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Evaluate the latest biomarker testing strategies in prostate, bladder, and lung cancer, including their impact on treatment decision-making
- Integrate all members of the care team in strategies to provide equitable biomarker testing in community oncology settings
- Identify the root causes of health inequity in cancer care
- Incorporate action-oriented strategies to address unconscious bias and patient social determinants of health (SDoH) in cancer care management

Faculty

Diana Brixner, BPharm, PhD, FAMCP (Moderator)
Emeritus Professor
Department of Pharmacotherapy
University of Utah
Salt Lake City, Utah

Zach Rivers, PharmD, PhD
Senior Scientist II
Tempus AI, Inc
Chicago, Illinois

Dusty Donaldson
Patient Advocate
LiveLung
High Point, North Carolina

ADDRESSING BARRIERS IN

Advancing Equitable Biomarker Testing in Community Oncology

Accreditation

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME)

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC)

This activity is designated for 1.5 contact hours. **Note to Nurse Practitioners:** The content of this CNE activity pertains to Pharmacology. **California Residents:** Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 1.5 Contact Hours.

PAs (AAPA)

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Pharmacists (ACPE)

This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-24-100-L01-P).

RCP Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Certificate of Participation

This activity was certified for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™.

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ADDRESSING BARRIERS IN

Advancing Equitable Biomarker Testing in Community Oncology

Faculty

Diana Brixner, BPharm, PhD, FAMCP (Moderator)

Emeritus Professor

Department of Pharmacotherapy

University of Utah

Salt Lake City, Utah

DISCLOSURES

Dr. Brixner reports the following financial relationships:

Advisory Board: Bayer and Jazz Pharmaceuticals, Inc.

Consultant: LEO Pharma; Millcrreek Outcomes Group, LLC; Sanofi; and Tandem Therapeutics

Grants: Dexcom, Inc.

Diana Brixner, BPharm, PhD, FAMCP is Emeritus Professor in the Department of Pharmacotherapy and is a Founder of the Pharmacotherapy Outcomes Research Center (PORC) at the University of Utah in Salt Lake City, UT. She has been a member of both the Huntsman Cancer Institute Cancer Control and Population Sciences and the Center for Genomic Medicine. She also serves as a principal of the Millcreek Outcomes Group, LLC where she consults on translating evidence to value to support payer decision making. Prior to her academic appointment in 2002 Dr. Brixner worked both in the biotech (NeoRx) and pharmaceutical (SmithKline Beecham, Novartis) industry focused on value assessment of their technologies in the early years of the field. Dr. Brixner was a Past President of both the Academy of Managed Care Pharmacy (AMCP) and International Society of Pharmacoeconomics and Outcomes Research (ISPOR). She has served as a one-year Scholar-in-Residence for AMCP, recently served on the scientific advisory board of Lumanity and is a member of the Executive Board of the International Market Access Society.

Dr. Brixner received her B.S. degree in 1982 from the University of Rhode Island, Pharmacy. In 1987 she received her Ph.D. in Medicinal Chemistry from the University of Utah. She received a Modeling Approaches for Health Technology Assessment Certificate in 2010, a Clinical Epidemiology Certificate in 2013 and a Certificate in the Introduction to Health Technology Assessment in 2015 from the University of Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria where she did a sabbatical in 2011.

Dr. Brixner's research focus is on the design, conduct, and communication of pharmacoeconomic and outcomes research studies to demonstrate the value of pharmaceutical and related therapies from the perspective of the private and public payer. Much of her work is focused on oncology and personalized medicine. She has published over 150 articles in peer-reviewed journals, authored three book chapters, has one issued patent, and has been an invited speaker at a variety of national and international professional meetings.

ADDRESSING BARRIERS IN

Advancing Equitable Biomarker Testing in Community Oncology

Zach Rivers, PharmD, PhD

Senior Scientist II

Tempus AI, Inc

Chicago, Illinois

DISCLOSURES

Dr. Rivers reports the following financial relationships:

Stock Shareholder (ownership interest): Tempus AI, Inc.

Employment: Tempus AI, Inc.

Zach Rivers, PharmD, PhD is a passionate clinician-scientist with over 15 years of experience in outpatient infusion and oral chemotherapy. Dr. Rivers' research is centered on integrating personalized and precision medicine into cancer care utilizing large datasets to identify opportunities for precision medicine and develop health economic simulation models to assess the impact of novel biomarkers on health policy and implementation. He is especially interested in how different biomarker testing approaches can increase health equity in traditionally underserved populations.



Dusty Donaldson

Patient Advocate

LiveLung

High Point, North Carolina

DISCLOSURES

Ms. Donaldson reports no financial relationships to disclose.

Dusty Donaldson is Founder and Executive Director of LiveLung, a 501c3 nonprofit serving the lung cancer community. She is also President of the Lung Cancer Action Network (LungCAN), a collaborative association of lung cancer nonprofit organizations and patient advocacy groups. In 2016, she co-authored the book "*The ABCs of Lung Cancer for Patients and Advocates*," and is working on the 2nd Edition soon to be released. Dusty has been a reviewer for lung cancer research proposals for the American Society of Clinical Oncology's (ASCO's) Conquer Cancer Foundation and the Congressionally Directed Medial Research Program's Lung Cancer Research Program. She is a contributing writer for www.lungcancer.net and serves on the National Lung Cancer Roundtable's Survivorship, Stigma & Nihilism Task Group. In 2022, Dusty received the International Association for the Study of Lung Cancer (IASLC) Patient Advocate Educational Award. Prior to being diagnosed with early-stage lung cancer in 2005, Dusty was a journalist and public relations professional. She earned undergraduate and graduate degrees in journalism.

ADDRESSING BARRIERS IN

Advancing Equitable Biomarker Testing in Community Oncology

Disclosure Declarations

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Peer Reviewers

Alaa Bawaneh, MD, PhD—no disclosures to report.

Andrea Edwards, PA-C—no disclosures to report.

CMEO Staff/Planners

Mary Gleason, PhD, CHCP—no disclosures to report.

Nichole Lainhart—no disclosures to report.

David Modrak, PhD—no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP—no disclosures to report.

Sandra Caballero, PharmD—no disclosures to report.

Sharon Tordoff—no disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the U.S. Food and Drug Administration (FDA). The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

ADDRESSING BARRIERS IN

Advancing Equitable Biomarker Testing in Community Oncology

Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty. Please see additional information below.

ASK FACULTY A QUESTION

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

VIEW AND TAKE NOTES ON PRESENTATION SLIDES

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to create an account.

Downloadable Resources

Downloadable resources will be available at **cmeoutfitters.com/biomarkerresources**.

Engage with Us

Follow us **@cmeoutfitters** for announcements about upcoming CME opportunities, healthcare news, and more!

Thank you for joining us today!

CME OUTFITTERS